

AML ID	mutation
AML1098	TSC1 c.1798C>T p.Q600* at 79%
AML1162	TSC2 c2974 C>T (p.Q992*), exon 26 – in 41.33% of 1196 reads; TSC2 c5226 indels (), exon 40 – in 12.86% of 916 reads
AML1166	TSC2 c.4537G>T (p.E1513*), exon 35 - in 35% of 343 reads; TSC2 c.4442dup (p.S1482Efs*42), exon 34 - in 36% of 297 reads
AML1167	TSC2 c.1372C>T (p.R458*), exon 13 – in 47.56% of 1214 reads
AML1171	TSC2 c.1111_119+1delinsTC (), exon 11 - in 19% of 146 reads
AML1172	TSC1 c.2074C>T (p.R692*), exon 17 - in 12% of 316 reads; TSC1 c.989_1011dup (p.I338*), exon 10 - in 4% of 304 reads

Supplementary table. Mutations identified in AML tumors. Genetic mutations identified in each AML tumor are listed.




Supplementary Fig.1 Pathological images for AML and LAM specimen.

Pathological images of AML samples (upper panel) and LAM samples (lower panel). scale bar: 100µm. Each image is representative of 10 areas of each sample.




### Supplementary Fig.2 Global single cell analysis of AML and LAM, related to Fig. 1.

- a. Expression of representative marker genes for cell types defined in AML. Red color shows the averaged normalized expression levels of marker genes.
- b. Average expression of five tumor marker genes in AML (left) and LAM (right).
- c. Graph-based clustering of mesenchymal cell population results in eight clusters.
- d. Cell fraction for each AML patient across cell types.
- e. Cell fraction for each LAM patient across cell types.
- f. Expression of representative marker genes for macrophages and proliferating cells defined in LAM. Red color shows the averaged normalized expression levels of marker genes.




#### Supplementary Fig.3 Marker gene expression in AML, related to Fig. 1.

- a. Identification of tumor cells (left) and tumor associated fibroblasts (TAF) (right) using marker genes shown. Cells expressed at least 2 marker genes above median value of corresponding genes across all cells were annotated as tumor cell or TAF, shown in red.
- b. Upper panel: violin plots showing representative upregulated genes in AML cells. The y axis represents the normalized gene expression. Lower panel: feature plots of these genes.
- c. Upper panel: violin plots showing expression of four long non-coding RNAs (IncRNAs). The y axis represents normalized gene expression. Lower panel: feature plots of these genes.
- d. Representative regulons enriched in AML cells. First row: expression of transcription factors. Second row: regulon activities of these transcription factors.
- e. Expression of *MDK* and *GPNMB* assessed by bulk RNA-Seq comparing AML tumors with normal kidneys. \*\*\*: MDK p-value=0.0001; GPNMB p-value=7.5e-06, two-sided t-test.
- f. Expression and regulon activity of *SP1* in AML cells.
- g. Expression of *HIF1A* in AML cells.




#### Supplementary Fig.4 Identification of two distinct cell states in AML/LAM cells, related to Fig. 2.


- a. Feature plot showing averaged expression of *MGP*, *BGN*, *PRELP*, *LUM*, *MMP2*, *DCN* (left) and *TAGLN*, *CNN1*, *ACTA2*, *MYL9*, *MYH11*, *TPM2* (right).
- b. Feature plot showing expression of *TCF21*.
- c. Feature plot showing expression of SOX4 and TCF4.
- d. Pathways enriched in SLS population, calculated using differentially expressed genes in cluster 1 (SLS) compared to cluster 2 (IS). Red: pathways enriched in SLS population; Blue: pathways enriched in IS population; x-axis: pathway activity score.
- e. Feature plots showing representative inflammatory genes upregulated in the IS population.
- f. Feature plots showing representative genes upregulated in the SLS population.
- g. Feature plots showing representative genes upregulated in the IS population.
- h. Expression of dormancy marker genes in TSC2-null 621-101 cells before and after estradiol treatment.
- i. Representative RNAScope images of MDK expression in each AML tumor analyzed.




#### Supplementary Fig.5 Expression of marker genes in LAM, related to Fig. 2.


- a. Feature plots showing expression of dormancy genes in LAM cells.
- b. ELISA assessment of serum MDK levels in healthy cohorts (n=19) and in LAM patients (n=20). \*: p-value=0.0361, two-sided t-test.













#### Supplementary Fig.6 In vitro experiment showing SLS cells are rapamycin tolerant, related to Fig. 3.


- a. Expression of genes identified as upregulated in AML cells in this study before and after rapamycin treatment in the primary culture.
- b. Expression of genes upregulated in SLS (refer to Supplementary Fig. 4f) in the control group.
- c. Expression of dormancy marker genes in the control group.
- d. Tumor volume relative to pre-treatment tumor volume. Data are presented as mean ± SD. Tumor volume was measure immediately before each treatment. TTJ xenograft mice (n=6 per group) were treated 3 times/wk with DMSO, iMDK (9mg/kg), rapamycin (3mg/kg), or combined iMDK (9mg/kg) and rapamycin (3mg/kg).
- e. Expression of MDK across cancer types and matched normal tissues (data obtained from TCGA). Box plots show the first quartile, median, and the third quartile. P-value Significant Codes: 0 ≤ \*\*\* < 0.001 ≤ \*\* < 0.01 ≤ \* < 0.05 ≤ . < 0.1. Refer number of RNA-seq datasets for each cancer type: <u>https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga/studied-cancers</u>.
- f. Cell growth inhibited by combination treatment of rapamycin and iMDK on 3 bladder cancer cell lines. Left panel: microscopy pictures showing growth of 3 bladder cancer cell lines treated with 20nM rapamycin alone (first column) or combination treatment of 20nM rapamycin and 1µM iMKD (second column) for 6 days. Scale bar, 100 µm (for all images). Right panel: cell proliferation, assessed by crystal violet assay, of bladder cell line HT1376 on the treatment of DMSO (vehicle), 20nM rapamycin, 1µM iMDK or combination of 20nM rapamycin and 1µM iMDK for 14 days. All experiments were replicated 3 times. Data are presented as mean ± SD.





### Supplementary Fig.7 Remodeling of endothelial cells, related to Fig. 4.

- a. Fraction of endothelial cells in IS (n=2) and SLS (n=3) tumors identified in IHC data.
- b. Expression of VEGFA in AML cells.
- c. Re-clustering of 20,772 endothelial cells (pooled from normal kidney and AML tumor) revealed 14 clusters.
- d. Expression of lymphatic endothelial marker genes (left) and blood endothelial marker genes (right) in endothelial cell clusters. One cluster of 646 cells (cluster 3; PDPN+, PROX1+ and LYVE1+) was composed of lymphatic endothelial cells (LECs) and was derived solely from tumor. Fourteen clusters of blood endothelial cells (FLT1+ and PLVAP+) were identified. Subtypes of endothelial cells were annotated based on published cell markers<sup>119</sup>.
- e. UMAP showing averaged expression of representative genes specifically expressed in endothelial cells (ECs) derived from AML tumors (left) or from matched normal tissues (right). Eleven of clusters were primarily tumor-derived (*PLVAP*+ and *APOLD1*+) and three clusters were primarily normal kidney-derived (*SOST*+ and *CRHBP*+).
- f. Feature plots showing expression of CCL21 (C-C Motif Chemokine Ligand 21), TBX1 and NRP2. These genes were observed specifically in tumor LECs. High expression of CCL21 promotes immune cells migration and tumor metastasis<sup>120</sup>. High expression of TBX1 is required for lymphatic vessel development<sup>121</sup>. NRP2 has been reported to be involved in sprouting lymphangiogenesis<sup>122</sup>.
- g. Hallmark pathways enriched in tumor-associated endothelial cells. Analysis of hallmark pathway gene signatures comparing all tumor-derived endothelial cells versus normal kidney-derived endothelial cells revealed stronger fatty acid metabolism in tumor-associated endothelial cells. Fatty acid metabolism plays a critical role in lymphatic differentiation and development by providing energy resources for cell proliferation and epigenetic regulation<sup>123</sup>.
- h. Expression and regulon activity of NR2F1 and NR2F2. Left two panels: expression of NR2F1 and NR2F2; right two panels: regulon activity of these transcription factors. Regulon analysis identified candidates that may underlie these gene expression differences in LECs, including transcription factors such as NR2F1 and NR2F2 that are highly expressed in tumor-derived LECs specifically. The genetic networks regulated by these transcription factors also showed high activity in LECs. NR2F2 is of particular interest in LAM because of its identification as a GWAS susceptibility locus<sup>124</sup>. NR2F2 has been shown to physically and functionally interact with PROX1 to regulate LEC-fate specification<sup>125,126</sup> and promote the formation of lymphatic vasculature<sup>122</sup>. NR2F2 controls sprouting lymphangiogenesis by transcriptional up-regulation of NRP2, a co-receptor for VEGF-C<sup>127</sup>. NR2F1 has recently been shown to be required for vascular development<sup>128</sup>.










Sh.

FGL1

\$

Expression Level

0.75 -0.50 -0.25 -0.00 -



CDH2

\$

0.75 0.50 0.25

0.00

5

PDCD1LG2



0.75


HLA-DRA

0.12

0.10


0.08

0.06



### Supplementary Fig.8 Characterization of T cells related to Fig. 5.

- a. Pathways enriched in T cells from tumor samples compared to those from matched normal tissues. Red bars represent pathways enriched in T cells from tumor samples; blue bars represent pathways enriched in T cells from matched normal tissues.
- b. UMAP plot of cell origin.
- c. Averaged expression of MKI67, MCM7, and PCNA in T cells.
- d. Representative images of CD3 IHC of 5 AML tumors and 4 matched normal samples.
- e. Feature plots showing expression of checkpoint markers in T cells.
- f. Bar plot showing fraction of T cells in SLS (n=4) versus IS (n=2) dominant tumors.
- g. Expression profiles of immune checkpoint ligands: TIGIT ligands (*PVR*, *NECTIN2*), BTLA ligand (*TNFRSF14*), LAG3 ligand (*HLA-DRA*, *FGL1*), *KLRG1* ligand (*CDH1*, *CDH2*), and PD-1 ligands (*CD274*, *PDCD1LG2*). The y axis represents the normalized gene expression value.



tSNE\_1


tSNE\_1

tSNE\_1

tSNE\_1

## Supplementary Fig.9 Suppressive immune microenvironment in AML, related to Fig. 6.

- a. Violin plot of expression of immune checkpoint genes in macrophages obtained from tumors or from matched normal kidneys.
- b. Representative images of Nanostring 12 ROIs of one SLS-dominant tumor and 12 ROIs of one IS-dominant tumor. Scale bars, 100  $\mu$ m.
- c. Inferred interactions between tumor cells and macrophages calculated by integrative analysis of spatial transcriptomics of the representative IS-dominant tumor (12 ROIs) and scRNA-Seq. x-axis displays relative expression of genes in single cell data. Only genes that are expressed in both single cell data and spatial transcriptomics data are shown. Left side are genes relatively highly expressed in tumor cells; right side are genes relatively highly expressed in macrophages. Y-axis displays Pearson Correlation Coefficient (PCC) of gene expression with macrophage frequency in spatial transcriptomics data. Genes with log-ratio less than -1.5 and correlation coefficient higher than 0.4 are colored. *APOE*: PCC=0.49, p=0.1 (correlation test, two-sided).
- d. Similar analysis as in Fig. 6d, but calculated by integrative analysis of bulk RNA-seq data from a published dataset<sup>8</sup> and scRNA-seq. *APOE*: PCC=0.55, p=0.1 (correlation test, two-sided).
- e. Feature plots showing expression of IL7R, GZMK, GZMH, IFITM1 in macrophages.
- f. Feature plots showing expression of marker genes of tumor-associated macrophages, including *CD163*, *MRC1*, *TREM2*, *VEGFA*.



С

# Supplementary Fig.10 Molecular interactions between tumor and tumor microenvironment inferred by ligand-receptor co-expression, related to Fig. 7.

- a. Pathways enriched in plasma cells and follicular B cells obtained from tumors, and enriched in B cells obtained from matched normal tissues.
- b. Feature plots showing expression of *CLEC9A* and *XCR1* in dendritic cells.
- c. Pathways enriched in each cluster of dendritic cells colored by column bar.
- d. Interactions between B cells and other cell types in SLS-dominant tumors, calculated as the product of the average ligand expression and average receptor expression. Only interactions with a score greater than 1 across any cell type pair are displayed. Each column shows a pair of cell types, and each row shows the ligand-receptor pair. The color indicates interaction score. Column label: cell type expressing the ligand and cell type expressing the receptor are separated by "\_". Row label: ligand and receptor are separated by "\_".
- e. Interactions between T cells and other cell types in SLS-dominant tumors, calculated as the product of the average ligand expression and average receptor expression. Only interactions with a score greater than 1 across any cell type pair are displayed.
- f. Interactions between NK cells and other cell types in SLS-dominant tumors. Only interactions with a score greater than 1 across any cell type pair are displayed.
- g. Interactions between tumor cells and other cell types in SLS-dominant tumors. Only interactions with a score greater than 1 across any cell type pair are displayed.

Supplementary table 1. Patient information.

AML ID mutation

AML1098 TSC1 c.1798C>T p.Q600\* at 79%

TSC2 c2974 C>T (p.Q992\*), exon 26 – in 41.33% of 1196 reads; TSC2 c5226 indels (), exon AML1162 40 – in 12.86% of 916 reads

TSC2 c.4537G>T (p.E1513\*), exon 35 - in 35% of 343 reads; TSC2 c.4442dup

AML1166 (p.S1482Efs\*42), exon 34 - in 36% of 297 reads

AML1167 TSC2 c.1372C>T (p.R458\*), exon 13 – in 47.56% of 1214 reads

AML1171 TSC2 c.1111\_1119+1delinsTC (), exon 11 - in 19% of 146 reads

TSC1 c.2074C>T (p.R692\*), exon 17 - in 12% of 316 reads; TSC1 c.989\_1011dup (p.I338\*), AML1172 exon 10 - in 4% of 304 reads